Download Markey Cancer Center Nurses` Guide

Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
Bumetanide
(Bumex)
Butorphanol Tartrate
(Stadol)
Cosyntropin
(Cortrosyn)
Dexamethasone Sodium Phosphate
(Decadron)
Dextrose 50%
Diazepam
(Valium)
Diphenhydramine HCL
(Benadryl)
Dolasetron Mesylate
(Anzemet)
Droperidol
(Inapsine)
Epinephrine
(Adrenaline Chloride)
Famotidine
(Pepcid)
Flumazenil
(Romazicon, Mazicon)
Furosemide
(Lasix)
Glucagon
(Glua Gen)
Glycopyrrolate
(Robinul)
Granisitron HCL
(Kytril)
Haldoperidol
(Haldol)
Heparin
(Heparin, Hep-Lock)
Hydralazine HCL
(Apresoline)
Hydrocortisone Sodium Succinate
(Solu-Cortef)
Hydromorphone
(Dilaudid)
Insulin – Regular Only
Ketorolac
(Toradol)
Labetalol
(Normodyne, Trandate)
Leucovorin Calcium
(Wellcovorin)
Levothyroxine
(Synthroid)
Lorazepam
(Ativan)
Meperidine
(Demerol)
Methylprednisolone Sodium Succinate
(Solu-Medrol)
Metoclopramide
(Reglan)
Morphine
(MSO4)
Muromonab-CD3
(Orthoclone, OKT3)
*BMT Unit ONLY
Naloxone
(Narcan)
Pantoprazole
(Protonix)
Promethazine
(Phenergan)
*Via Central or PICC Line Only
Sodium Bicarbonate
(NaHCO3, Bicarb)
Torsemide
(Demadex)
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
Atropine
Bumetanide
(Bumex)
Butorphanol
Tartrate
(Stadol)
Cosyntropin
(Cortrosyn)
Dexamethasone
Sodium Phosphate
(Decadron)
THERAPEUTIC
CATEGORY/
INDICATIONS
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
Antiarrhythmic/
Anticholinergic/
Treat symptomatic
bradycardia, Pre-op
antidote for certain
insecticide
poisoning
Diuretic/
Acute pulmonary
edema, CHF, renal
disease
Pre-op: 0.40.6mg
2 mg
1mg/ml
1 mg or less over
1 minute
Narcotic-Opioid
analgesic/
Relief of modsevere pain
Diagnostic Agent
0.5-2 mg
q 3-4 hours
4mg/do
se
0.25mg
1mg
Antiemetic esp. for
high dose chemo &
radiation; Antiinflammatory,
Cerebral edema
4mg
Highly
variable
based
on
disease/
pt.
respons
e (20100
mg)
Bradycardia:
0.4-1 mg q 3-5
min to max of 2
mg
0.5-2mg
10mg/d
ay
2mg/ml
ADMINISTRATION
CONSIDERATIONS
Dry mouth, dizziness, palpitations,
urinary retention, nervousness,
weakness.
2mg over 2
minutes
Pain at injection
site
2mg over 3-5
minutes
Also supplied as
nasal spray
10mg.ml
2 minutes
4mg/ml
Over 1 minute
maximum,
slower if itching
Over 3-5 min is
better.
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
Contraindicated
in pts. with
psychosis, AIDS,
TB, VRE, fungal
infections
Risk of ototoxicity if concurrent use
with aminoglycoside antibiotics.
Multiple drug interactions. Dizziness,
weakness, N&V, orthostatic
hypotension, hypokalemia, polyuria
N&V, sedation, diplopia, palpitations,
respiratory depression, caution with
ambulation
Peak cortisol concentration occurs 4560 min after administration
Insomnia, nervousness, increased
appetite, thrombocytopenia, fluid
retention,
Watch for GI bleeding, epistaxis
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
THERAPEUTIC
CATEGORY/
INDICATIONS
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
Phlebitis risk,
pain at injection
site. Best per
central line VAD
-Phlebitis risk,
pain at injection
site-use large
vein
-Flumazenil
(Romazicon) is
the antagonist
-Incompatible
with most other
drugs & solns.
Push only in NS
or D5NS very
close to IV site
Dilute to
25mg/ml in
D5W or NS
Dextrose 50%
Symptomatic
hypoglycemia
20 - 50ml
of 50% solution
-
20 - 50ml
of 50%
solution
10ml/minute
Diazepam
(Valium)
Benzodiazipine;
Seizure,
Anxiety,
Alcohol withdrawal
Seizures: 5-10 mg
initial, repeat at 10
min intervals to
max 30 mg
Anxiety: 2-5mg
initial, repeat q3-4
hrs prn
Alcohol
Withdrawal: 10 mg
initial, repeat 5-10
mg q 3-4 hrs prn.
30mg/8
hrs
5mg/ml
2- 5mg/minute
Diphenhydramine
HCL
(Benadryl)
Antihistamine;
Histamine 1
Antagonist/
Alleviate allergic
symptoms
5 HT3 Blocker –
Antiemetic/
Prevent & treat
chemo induced and
post-op N&V
25-50mg Q24H
50mg/d
ose400
mg/day
50mg/ml
25mg/minute
12.5mg/
0.625 ml
100 mg/30
seconds
Dolasetron Mesylate
(Anzemet)
12.5 mg over 30
seconds
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
Hyperglycemia, confusion, tissue
necrosis with extravasation of
peripheral infusion.
Bradycardia; tachycardia, drowsiness,
hypotension, hypoventilation, urinary
retention, caution in elderly, do not
use with acute narrow angle glaucoma
Hypotension, tachycardia, sedation,
dizziness, insomnia, caution in asthma
HTN, Headache, dizziness,
tachycardia and urinary retention.
Caution in patients at risk for
prolonged QT interval
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
THERAPEUTIC
CATEGORY/
INDICATIONS
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
10 mg
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
2.5- 10 mg/min
*Drug Carries
Black Box
WarningReserve for pts
who do not
respond to
alternatives
Laryngospasm, hypotension
especially orthostatic, hallucinations,
sedation, prolonged QT interval.
Check V/S at 30 min (peak effect)
Usual
conc. is
1mg/10ml
1 mg over 1-2
seconds
Watch for
injection site
blanching/
extravasation
-Tachycardia, hypertension,
nervousness, restlessness, headache,
dizziness
HR, BP
-Note: One mg = 1ml of 1:1000 soln
OR 10ml of 1:10,000 soln
-Do not mix with alkaline solutions
Transient
irritation at IV
site
Dosage adjusted
in renal failure
Use large vein &
free flowing IV
to minimize pain
at injection site
Headaches, dizziness, confusion,
mental status changes
Droperidol
(Inapsine)
Nausea & vomiting
Premed for OR
2.5- 10 mg per
min
Epinephrine
(Adrenaline
Chloride)
Sympathomimetic,
Cardiac Arrest,
Hypersensitivity
reactions
1mg q 3-5 min.
during cardiac
arrest
Famotidine
(Pepcid)
Gastrointestinal,
Histamine 2
Antagonist
20mg Q12H
40mg
20mg/5 to
10ml
20mg/2 minutes
Flumazenil
(Romazicon,
Mazicon)
Benzodiazipine
antagonist
0.2mg initial,
them can repeat
with 0.3mg
Give no
more
than
1mg
per
dose or
3mg/ho
ur
0.1mg/ml
0.2mg over 1530 seconds
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
Pt. may need additional doses in case
of re-sedation. Caution in pts. at risk
for or being treated for seizures
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
THERAPEUTIC
CATEGORY/
INDICATIONS
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
80 mg
but can
vary
widely
10mg/ml
1-2 minutes
Rapid and high
dose admin. can
cause
irreversible
hearing loss
Hypotension, headache, dizziness
1mg/minute
May precipitate
with NS,
potassium &
calcium.
Unstable hypoglycemic diabetic may
not respond & will need dextrose IV
instead.
N&V, hypokalemia in overdose,
urticaria, respiratory distress,
hypotension.
Furosemide
(Lasix)
Loop Diuretic for
pulmonary edema,
fluid overload
40 mg
Glucagon
(Glua Gen)
-Emergency
treatment of
symptomatic
hypoglycemia
-Diagnostic aid in
some radiological
exams
Anticholinergic/
Preop: to diminish
secretions & block
cardiac vagal
reflexes
0.5-1 mg.
May be
repeated 1-2
times.
5HT3 Blocker
Prevention of N/V
secondary to
chemotherapy
Antipsychotic/
Acute psychiatric
episodes
Nausea & vomiting
10 mcg/kg
given 30 min
prior to chemo
dose
2-25 mg
Glycopyrrolate
(Robinul)
Granisetron HCL
(Kytril)
Haldoperidol
(Haldol)
Compatible
with D5W
0.0044 mg./kg
30 min prior to
anesthesia
0.2mg.ml
Varies
with
patient
100mg/ml
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
0.2 mg over 1-2
minutes using
free-flowing IV
line
Blurred vision, dry mouth, N&V,
urinary hesitancy & retention
Undiluted over
30 seconds
Headache, diarrhea, constipation,
hypertension, fever.
5mg/minute
Start with lower
doses in geriatric
patients
Drowsiness, extrapyramidal
symptoms, hypotension, tachycardia,
bradycardia, suppression of cough
reflex, dry mouth, N&V
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
Heparin
(Heparin Hep-Lock)
THERAPEUTIC
CATEGORY/
INDICATIONS
Anticoagulant/
DVT, Pulmonary
Embolism, MI
-Final flush for
Groshong catheter
in low dose
Hydralazine HCL
(Apresoline)
Antihypertensive/
Severe essential
hypertension, when
need to lower BP is
urgent
Hydrocortisone
Sodium Succinate
(Solu-Cortef)
Hydromorphone
(Dilaudid)
Narcotic Analgesic
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
100-4000
units
Initial bolus:
60-80
units/kg
Infusion:
12-18
units/kg/hr
10-40 mg
Repeated as
necessary
10000
units/ml
Over 1 minute
Reversal agent:
Protamine
Takes 6 hours to
see effects of
dose change
Bleeding, APTT, Hct, Hgb
Thrombocytopenia (HIT - Heparin
Induced Thrombocytopenia)
20 mg/ml
Slow IVP
Caution in CVA-may increase
intercranial pressure. Headache,
N&V, palpitations, angina,
tachycardia, diarrhea. Elderly may be
more sensitive to hypotensive effects.
*Do not confuse with hydroxyzine.
Succinate =
100-500mg
Succinate=
over at
least 30 sec
-Do not give
with dextrose
containing
solutions
-Undergoes color
changes in most
IV solutions.
This does not
indicate loss of
potency
-Succinate
comes in “Mixo-vial, mix
gently
1-4mg q 2-6 hrs
prn
4mg/ml
Each 2 mg over
2-5 minutes
Nalxone
(Narcan) is
reversal agent
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
Insomnia, nervousness. May cause
hyperglycemia in diabetics. Caution
in TB & fungal infections & antibiotic
resistant infections.
Alert: salt formations are not
interchangeable
Alert: do not confuse Solu-Cortef
with Solu-Medrol
Palpitations, hypotension,
constipation, dizziness, drowsiness,
BP, RR
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
THERAPEUTIC
CATEGORY/
INDICATIONS
TYPICAL ADULT
DOSE
Insulin
(Regular Only)
Pancreatic
Hormone/
Hyperglycemia,
DKA, Hyperkalemia
0.1-0.5 units/kg
IV bolus
Ketorolac
(Toradol)
NSAID/
Short term
management of
mod-severe pain
15 mg-30mg IV
q 6 hours
Labetalol
(Normodyne)
(Trandate)
Antihypertensive
Leucovorin Calcium
(Wellcovorin)
Folinic acid
-High dose
methotrexate rescue.
20 mg initial.
Additional
doses of 4080mg q 10 min.
until max 300
mg
Rescue: Based
on methotrexate
level but
roughly
10mg/m2
-Advanced
colorectal cancer
(followed by 5FU as
2nd infusion)
MAXIM
UM
ADULT
DOSE
120
mg/day,
max 5
days
MAXIMUM
CONCENTR
ATION
30 mg/ml
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
Over 10 seconds
-ONLY Regular
Insulin may be
given IV
-Hyperkalemia:
10 units in
conjunction with
dextrose and
sodium
bicarbonate
Do not
administer
intrathecal or
epidural routes
Requires renal
dose adjustment
Over > 15
seconds
20 mg over 2
minutes
25mg/ml
Over 3 minutes
or longer. Do
not exceed 160
mg/minute
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
Monitor Finger Stick Blood Sugars
Edema, drowsiness, headache, renal
toxicity. Do not administer to pts
with active or recent bleeding. Do not
use as pre-op analgesic. Avoid if
already taking ASA or NSAIDS.
Dizziness, orthostatic hypotension,
vivid dreams, N&V, bronchospasm,
dyspnea, arrhythmias, nasal stuffiness
-Pain at injection
site
-Protect form
heat & light
Allergic reactions.
Do not confuse leucovorin (folinic
acid) with folic acid.
Follow leucovorin rescue
schedule/protocol VERY closely.
Cancer: 20200mg/m2
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
THERAPEUTIC
CATEGORY/
INDICATIONS
Levothyroxine
(Synthroid)
Thyroid hormone/
Replacement
therapy in
hypothyroidism
Lorazepam
(Ativan)
Benzodiazipine/
Anticonvulsant,
sedation, anxiety,
agitation
Meperidine
(Demerol)
Narcotic Analgesic
TYPICAL ADULT
DOSE
Initial dose:
200-500mcg,
then100-300 on
day two, then
maint. 50200mcg q day
Maintenance =
½ of oral dose
1-2 mg
25-150 mg
q 2-4 hrs prn
MAXIM
UM
ADULT
DOSE
8mg/12
hrs,
or 4mg
per
dose
MAXIMUM
CONCENTR
ATION
2mg/ml
100mg/ml
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
100mcg/min
-Do not mix with
any other IV
fluids
-Do not further
dilute drug
Symptoms of hyperthyroidism
(nervousness, tremor, headache
tachycardia, heat intolerance, etc.)
2mg/minute
-Flumazenil
(Romazicon) is
reversal agent
used to treat
respiratory
depression.
-Dilute with
equal volume
IVF
Sedation, hypotension, dizziness,
headache, amnesia, HR, BP, RR.
-Dilute to <
10mg/ml
-Contraindicated
in pt. taking
MAO inhibitor
& with pt. in
kidney failure
-Naloxone
(Narcan) is
reversal agent
Sedation, hypotension, dizziness,
constipation, BR, RR
Over 4-5 minutes
Can increase digoxin levels.
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
THERAPEUTIC
CATEGORY/
INDICATIONS
Methylprednisolone
Sodium Succinate
(Solu-Medrol)
Metoclopramide
(Reglan)
Morphine
Muromonab-CD3
(Orthoclone, OKT3)
*BMT Unit ONLY
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
Anti-inflammatory
agent Adrenal
Corticosteroid/
Severe inflammation
Immunosuppression
Prevent
infusion/allergic
reactions
Antiemetic/
Relief of
symptomatic GE
Reflux, facilitate
small bowel
intubation, N&V
post-op and assoc.
with chemo
Narcotic Analgesic
10-125 mg
-High
dose
regime
ns will
require
IVPB
route of
admin
10 mg
62.5mg/ml
Over 3-60
minutes
125mg / 3-5 min
250mg/15-30min
500mg/ 30min
1Gm/60min
-Rapid admin of
high doses can
cause circulatory
collapse.
-* Only the
succinate form
can be given IV
Insomnia, nervousness
BP, monitor blood glucose levels in
diabetic pts. Monitor Na+ and
potassium levels
5mg/ml
1-2 minutes
High doses
>10mg require
IVPB over 15
min.
Admin over < 1
min. may cause
intense anxiety
& restlessness
Caution with hypertension.
Contraindicated in GI bleed. Mental
depression, BP changes, restlessness,
drowsiness, dizziness, dystonic
reactions (extrapyramadal effects
treated Benadryl).
10mg/ml
1 mg/min
- Naloxone
(Narcan) is
reversal agent
Sedation, dizziness, heart palpitation,
hypotension, bradycardia,
constipation
BP, RR, Oxygen saturation
Immunosuppressive
Agent
5mg
1mg/ml
<1minute
Filter each dose
through a low
protein binding
0.22 micron
filter
Fever, chilling, dyspnea, wheezing,
chest pain, tachycardia, dizziness,
shortness of breath. Monitor all vital
signs including temperature.
5-10 mg
1-2mg/kg IV 30
min prior to
chemo
2-10 mg
q 2-4 hours prn
5mg
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
Naloxone
(Narcan)
Pantoprazole
(Protonix)
Promethazine
(Phenergan)
THERAPEUTIC
CATEGORY/
INDICATIONS
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
ADMINISTRATION
CONSIDERATIONS
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
Pure Opiod
Antagonist/
Treat respiratory
depression from
narcotic intake
0.4-2mg
24mg
1mg/ml
Over 2 minutes
-If pt. on chronic
opioids, give
<0.1 mg at a
time to avoid
reversal of pain
relief
Tachycardia, narcotic withdraw,
hypertension, hypotension, anxiety,
restlessness, HR, BP, RR
Note: duration of narcotic may exceed
that of Naloxone, monitor for return
of respiratory depression
Gastrointestinal;
Proton pump
inhibitor
Antiemetic
Antihistamine
40 mg
80 mg
4mg/ml
40mg/ 2 min
Injection site reactions, headache,
dyspepsia, and nausea
12.5-25mg
50mg
50mg/ml
25mg/min
Reconstitute
with 10ml, 0.9%
NaCl.
ALERT!
Extravasation
can lead to
EXTENSIVE
tissue damage.
Give ONLY via
Central or
PICC Line
-Push in cardiac
arrests only
-Tissue necrosis
if extravasation.
-inactivates
catecholamines
such as
dopamine,
epinephrine
-Precipitates if
given with
calcium
Edema, fluid overload,
hypernatremia, metabolic alkalosis
0.1-0.2 mg q 23 min until
desired reversal
of post-op
narcotic
depression
Via CENTRAL or
PICC line only, or
IVPB over 20 min.
Sodium Bicarbonate
(NaHCO3)
(Bicarb)
Alkalinization
Agent/
-Metabolic acidosis
(from cardiac arrest,
renal failure, DKA,
etc)
-Maintain alkaline
urine: tumor lysis
syndrome, trauma,
tricyclic
antidepressant drug
overdose
0.5-1 mEq/kg
Dose for renal
failure & DKA
based n ABG
1mg/ml
Rapid: 1-2
seconds
ALERT – ONLY given via Central or
PICC Line due to potential for tissue
damage with extravasation.
Hypotension, tachycardia, dizziness,
drowsiness.
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager
Markey Cancer Center Nurses’ Guide:
Intravenous Push (IVP) Drug List – Approved for RN Administration
Updated:
2/25/05
University of Kentucky Chandler Medical Center
GENERIC NAME
(BRAND NAME(S))
Torsemide
(Demadex)
ƒ
THERAPEUTIC
CATEGORY/
INDICATIONS
Diuretic/
HPT, CHF with
fluid overload, renal
& hepatic disease
TYPICAL ADULT
DOSE
MAXIM
UM
ADULT
DOSE
10-20 mg
MAXIMUM
CONCENTR
ATION
MAXIMUM RATE
OF
ADMINISTRATION
20mg over at
least two min
ADMINISTRATION
CONSIDERATIONS
ADVERSE EFFECTS/COMMENTS
MONITORING PARAMETERS
Contraindicated in anuria.
Hypokalemia, hyperglycemia, N&V,
headache, dizziness.
If the medication is not approved for IV push administration and alternative routes of administration are not available, approval
for this individual situation must be obtained through collaboration with pharmacy and the patient care manager
Updated: 02/04/03
Developed by: Jeanne Bouvier, Staff Development and Kim Hopper, PharmD
Approved by: Kimberley Hite, Tukea Talbot, Mary Lindsey Merrill
Contact person for revisions: Kimberley Hite ([email protected])
If medication is not approved for the IV push administration and alternative routes of administration are not available, approval for this individual
situation must be obtained through collaboration with pharmacy and the patient care manager